MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

This study concerns elderly patients with cancer with onco-geriatric assessment.

This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms

Age range

70 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU, Caen, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient aged over 70 years
Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.
Patient candidate for oncogeriatric assessment
Patient agree to participate in the study
Using the French language

Exclusion criteria

Primary central nervous system or cerebral metastasis
Evolutionary psychiatric pathology known (e.g. schizophrenia)
Severe Visual and / or Auditory Impairment
Patients unable to respond to cognitive tests
Patient (s) deprived of liberty, under guardianship or curatorship
Refusal of participation

Treatment and study plan

Passation of neuropsychological test

Other

Passation of MoCA and MMS tests associated with neuropsychological test

Primary outcomes

Evaluate the sensitivity of MoCA test

Time frame: Up 2 months after inclusion, before initiation of treatment

MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%

Sponsors and collaborators

Lead sponsor

Centre Francois Baclesse

Other

Collaborators

UCOG (Unite de coordination en Onco-Gériatrie)

Registry information

Acronym: MOCA-2

Important dates

Study start: 2017
Primary completion: 2023
Study completion: 2023
First posted: Oct 3, 2017
Registry last updated: Oct 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed